| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), Åbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
* To whom correspondence should be addressed. E-mail: juha.rinne{at}tyks.fi.
Abstract-- Background: PET studies with N-methyl-[11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB) have revealed an increased tracer uptake in several brain regions in Alzheimer disease (AD). Objective: To employ voxel-based analysis method to identify brain regions with significant increases in [11C]PIB uptake in AD vs healthy control subjects, indicative of increased amyloid accumulation in these regions. Methods: We studied 17 patients with AD and 11 control subjects with PET using [11C]PIB as tracer. Parametric images were computed by calculating a region-to-cerebellum ratio over 60 to 90 minutes in each voxel. Group differences in [11C]PIB uptake were analyzed with statistical parametric mapping (SPM) and automated region-of-interest (ROI) analysis. Results: SPM showed increased uptake (p < 0.001) in the frontal, parietal, and lateral temporal cortices as well as in the posterior cingulate and the striatum. No significant differences in uptake were found in the primary sensory and motor cortices, primary visual cortex, thalamus, and medial temporal lobe. These results were supported by automated ROI analysis, with most prominent increases in AD subjects in the frontal cortex ([11C]PIB uptake 163% of the control mean) and posterior cingulate (146%) followed by the parietal (146%) and temporal (145%) cortices and striatum (133%), as well as small increases in the occipital cortex (117%) and thalamus (115%). Conclusions: Voxel-based analysis revealed widespread distribution of increased [11C]PIB uptake in Alzheimer disease (AD). These findings are in accordance with the distribution and phases of amyloid pathology in AD, previously documented in postmortem studies.
This article has been cited by other articles:
|
|
 |
|
  N. M. Scheinin, S. Aalto, J. Koikkalainen, J. Lotjonen, M. Karrasch, N. Kemppainen, M. Viitanen, K. Nagren, S. Helin, M. Scheinin, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls Neurology, October 13, 2009; 73(15): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Okello, J. Koivunen, P. Edison, H. A. Archer, F. E. Turkheimer, K. Nagren, R. Bullock, Z. Walker, A. Kennedy, N. C. Fox, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study Neurology, September 8, 2009; 73(10): 754 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Lowe, B. J. Kemp, C. R. Jack Jr., M. Senjem, S. Weigand, M. Shiung, G. Smith, D. Knopman, B. Boeve, B. Mullan, et al. Comparison of 18F-FDG and PiB PET in Cognitive Impairment J. Nucl. Med., June 1, 2009; 50(6): 878 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Mormino, J. T. Kluth, C. M. Madison, G. D. Rabinovici, S. L. Baker, B. L. Miller, R. A. Koeppe, C. A. Mathis, M. W. Weiner, W. J. Jagust, et al. Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects Brain, May 1, 2009; 132(5): 1310 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Frisoni, M. Lorenzi, A. Caroli, N. Kemppainen, K. Nagren, and J. O. Rinne In vivo mapping of amyloid toxicity in Alzheimer disease Neurology, April 28, 2009; 72(17): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dai, O. L. Lopez, O. T. Carmichael, J. T. Becker, L. H. Kuller, and H. M. Gach Mild Cognitive Impairment and Alzheimer Disease: Patterns of Altered Cerebral Blood Flow at MR Imaging Radiology, March 1, 2009; 250(3): 856 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Fodero-Tavoletti, C. C. Rowe, C. A. McLean, L. Leone, Q.-X. Li, C. L. Masters, R. Cappai, and V. L. Villemagne Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias J. Nucl. Med., February 1, 2009; 50(2): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Edison, C C Rowe, J O Rinne, S Ng, I Ahmed, N Kemppainen, V L Villemagne, G O'Keefe, K Nagren, K R Chaudhury, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography J. Neurol. Neurosurg. Psychiatry, December 1, 2008; 79(12): 1331 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Leinonen, I. Alafuzoff, S. Aalto, T. Suotunen, S. Savolainen, K. Nagren, T. Tapiola, T. Pirttila, J. Rinne, J. E. Jaaskelainen, et al. Assessment of {beta}-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11-Labeled Pittsburgh Compound B Arch Neurol, October 1, 2008; 65(10): 1304 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Esposito, G. Giovacchini, J.-S. Liow, A. K. Bhattacharjee, D. Greenstein, M. Schapiro, M. Hallett, P. Herscovitch, W. C. Eckelman, R. E. Carson, et al. Imaging Neuroinflammation in Alzheimer's Disease with Radiolabeled Arachidonic Acid and PET J. Nucl. Med., September 1, 2008; 49(9): 1414 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sojkova, L. Beason-Held, Y. Zhou, Y. An, M. A. Kraut, W. Ye, L. Ferrucci, C. A. Mathis, W. E. Klunk, D. F. Wong, et al. Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern? J. Nucl. Med., September 1, 2008; 49(9): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mikhno, D. Devanand, G. Pelton, K. Cuasay, R. Gunn, N. Upton, R. Y. Lai, V. Libri, J. J. Mann, and R. V. Parsey Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease J. Nucl. Med., August 1, 2008; 49(8): 1262 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koivunen, A. Verkkoniemi, S. Aalto, A. Paetau, J.-P. Ahonen, M. Viitanen, K. Nagren, J. Rokka, M. Haaparanta, H. Kalimo, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease Brain, July 1, 2008; 131(7): 1845 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Remes, L. Laru, H. Tuominen, S. Aalto, N. Kemppainen, H. Mononen, K. Nagren, R. Parkkola, and J. O. Rinne Carbon 11-Labeled Pittsburgh Compound B Positron Emission Tomographic Amyloid Imaging in Patients With APP Locus Duplication Arch Neurol, April 1, 2008; 65(4): 540 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Jack Jr, V. J. Lowe, M. L. Senjem, S. D. Weigand, B. J. Kemp, M. M. Shiung, D. S. Knopman, B. F. Boeve, W. E. Klunk, C. A. Mathis, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain, March 1, 2008; 131(3): 665 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Salmi, R. M. Laitio, S. Aalto, A. T. Maksimow, J. W. Langsjo, K. K. Kaisti, R. Aantaa, V. Oikonen, L. Metsahonkala, K. Nagren, et al. Xenon Does Not Affect {gamma}-Aminobutyric Acid Type A Receptor Binding in Humans Anesth. Analg., January 1, 2008; 106(1): 129 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K HERHOLZ, S F CARTER, and M JONES Positron emission tomography imaging in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S160 - S167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Pike, G. Savage, V. L. Villemagne, S. Ng, S. A. Moss, P. Maruff, C. A. Mathis, W. E. Klunk, C. L. Masters, and C. C. Rowe {beta}-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain, November 1, 2007; 130(11): 2837 - 2844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Boxer, G. D. Rabinovici, V. Kepe, J. Goldman, A. J. Furst, S. -C. Huang, S. L. Baker, J. P. O'Neil, H. Chui, M. D. Geschwind, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease Neurology, July 17, 2007; 69(3): 283 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Klunk, J. C. Price, C. A. Mathis, N. D. Tsopelas, B. J. Lopresti, S. K. Ziolko, W. Bi, J. A. Hoge, A. D. Cohen, M. D. Ikonomovic, et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees J. Neurosci., June 6, 2007; 27(23): 6174 - 6184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Rowe, S. Ng, U. Ackermann, S. J. Gong, K. Pike, G. Savage, T. F. Cowie, K. L. Dickinson, P. Maruff, D. Darby, et al. Imaging {beta}-amyloid burden in aging and dementia Neurology, May 15, 2007; 68(20): 1718 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Kemppainen, S. Aalto, I. A. Wilson, K. Nagren, S. Helin, A. Bruck, V. Oikonen, M. Kailajarvi, M. Scheinin, M. Viitanen, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment Neurology, May 8, 2007; 68(19): 1603 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Rabinovici, A. J. Furst, J. P. O'Neil, C. A. Racine, E. C. Mormino, S. L. Baker, S. Chetty, P. Patel, T. A. Pagliaro, W. E. Klunk, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration Neurology, April 10, 2007; 68(15): 1205 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Bateman and D. Eidelberg Testing a test for Alzheimer disease Neurology, February 13, 2007; 68(7): 482 - 483. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Scheinin, T. K. Tolvanen, I. A. Wilson, E. M. Arponen, K. A. Nagren, and J. O. Rinne Biodistribution and Radiation Dosimetry of the Amyloid Imaging Agent 11C-PIB in Humans J. Nucl. Med., January 1, 2007; 48(1): 128 - 133. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
